Actively Recruiting
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Led by Dynavax Technologies Corporation · Updated on 2025-10-06
148
Participants Needed
3
Research Sites
57 weeks
Total Duration
On this page
Sponsors
D
Dynavax Technologies Corporation
Lead Sponsor
U
United States Department of Defense
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
CONDITIONS
Official Title
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 to 55 years of age
- Healthy or with stable pre-existing medical conditions without major medication changes or hospital visits in past 3 months
- Able to follow study schedule and procedures
- Able and willing to provide written informed consent
- If female and able to have children, must use effective contraception for 28 days before vaccination, have negative pregnancy tests before vaccination, and continue contraception for 3 months after last dose
- Women not of childbearing potential include those with documented hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or tubal ligation
You will not qualify if you...
- History of plague disease or previous plague vaccine
- Active tuberculosis or other systemic infections
- History or positive test for HIV, hepatitis B, or hepatitis C
- History of autoimmune disorders
- Sensitivity to any vaccine components
- Body mass index 30 kg/m2 or higher
- Recent use of certain vaccines or immune-modifying drugs within specific timeframes before trial injections
- Pregnant, breastfeeding, or planning pregnancy
- Undergoing or expected to undergo chemotherapy or recent cancer diagnosis except certain skin cancers
- Any condition or treatment that could interfere with trial participation or results
- Fever of 386C (100.46F) or higher at vaccination
- History of heart attack or coronary artery disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
AMR- Miami
Miami, Florida, United States, 33134
Not Yet Recruiting
2
AMR- El Dorado
El Dorado, Kansas, United States, 67042
Actively Recruiting
3
AMR- Las Vegas
Las Vegas, Nevada, United States, 889119
Actively Recruiting
Research Team
O
Ouzama Henry, MD, Vice President, Clinical Development
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
PREVENTION
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here